Publications by authors named "Chad Patel"

Claim this Profile
T
TearCare system versus cyclosporine ophthalmic emulsion for the treatment of moderate-to-severe meibomian gland disease associated dry eye disease in the United States: a cost-utility analysis.
Nathan Lighthizer, Bonnie-Kim Schwertz, Thomas Chester, Roberta Longo, Phoenix Riley, Chad Patel

Expert Rev Pharmacoecon Outcomes Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma.
Gregory Mader, Federico Ghinelli, Francesca Torelli, Chad Patel, Cristina Masseria

Expert Rev Pharmacoecon Outcomes Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan.
Alpesh Amin, Allison Keshishian, Lien Vo, Qisu Zhang, Oluwaseyi Dina, Chad Patel

J Med Econ· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
Henry J Henk, Feng Cao, Kenneth Tuell, Kwanza Price, Prianka Singh, Chad Patel

Curr Med Res Opin· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
Jason Shafrin, Mahlet Gizaw Tebeka, Kwanza Price, Chad Patel, Kaleb Michaud

J Manag Care Spec Pharm· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents.
Anagha Nadkarni, Donna McMorrow, Chad Patel, Robert Fowler, David Smith

J Comp Eff Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
Laure Weijers, Christoph Baerwald, Francesco S Mennini, José M Rodríguez-Heredia, Martin J Bergman, Chad Patel

Rheumatol Int· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype.
Alyssa Goolsby Hunter, Lisa Rosenblatt, Chad Patel, Cori Blauer-Peterson, Beatrice Anduze-Faris

Curr Med Res Opin· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
Nazia Rashid, Antony T Lin, Gustavus Aranda, Kathy J Lin, Valerie N Guerrero, Chad Patel

J Med Econ· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
Hongbo Yang, Paresh Chaudhari, Zheng-Yi Zhou, Eric Q Wu, Chad Patel

Appl Health Econ Health Policy· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis